{"id":"NCT00809328","sponsor":"Pfizer","briefTitle":"The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)","officialTitle":"A Multicenter, Non-Randomized, Open Label Study Of Azithromycin Intravenous Followed By Oral Administration In Japanese Adult Subjects With Community Acquired Pneumonia (CAP) Requiring Initial Intravenous Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02","primaryCompletion":"2010-03","completion":"2010-03","firstPosted":"2008-12-17","resultsPosted":"2011-04-13","lastUpdate":"2011-05-19"},"enrollment":102,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Community Acquired Pneumonia (CAP)"],"interventions":[{"type":"DRUG","name":"Azithromycin","otherNames":[]}],"arms":[{"label":"Azithromycin","type":"EXPERIMENTAL"}],"summary":"Azithromycin has high rates of clinical response and eradication, wide spectrum of activity, so we suppose the development of the azithromycin injectable formulation in Japan would deliver benefit to patients of community acquired pneumonia.","primaryOutcome":{"measure":"Response Rate (Clinical Response, Data Review Committee Assessment)","timeFrame":"End of Treatment, Day 15 and Day 29","effectByArm":[{"arm":"Azithromycin","deltaMin":86.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":34,"countries":["Japan"]},"refs":{"pmids":["24477328"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0661191&StudyName=The%20Study%20Of%20Azithromycin%20Switch%20Therapy%20For%20Treatment%20Of%20Community%20Acquired%20Pneumonia%20%28CAP%29"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":102},"commonTop":["Diarrhoea","Constipation","Headache","Injection site pain","Insomnia"]}}